NEW YORK, December 30, 2025, 10:48 ET — Regular session
- Eli Lilly shares edged down about 0.2% in morning trading.
- A Reuters report said Lilly and Novo Nordisk are lowering obesity-drug prices in China, adding to global pricing scrutiny.
- An SEC filing showed Lilly Endowment Inc reported selling 2,629 shares in a recent transaction.
Eli Lilly and Company shares were down $1.73, or about 0.2%, at $1,077.00 in morning trading on Tuesday.
The move comes as investors focus on whether the weight-loss boom is entering a tougher phase on pricing, not just supply. Lilly’s obesity franchise has helped propel the stock, so any sign of discounting tends to land quickly with traders.
The issue matters now because competition is widening beyond the United States and into markets where access and affordability drive demand. For GLP-1 drugs — medicines that mimic a gut hormone to curb appetite and help control blood sugar — pricing can determine how fast adoption scales and how much profit companies keep.
Reuters reported that Novo Nordisk and Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, citing the Danish drugmaker and Chinese suppliers. A hospital WeChat account in Nanjing said Mounjaro prices would drop from Jan. 1, and a Meituan listing showed a projected price of about 445 yuan for a 10mg pen, down from 2,180 yuan; Novo confirmed it was adjusting Wegovy prices after Chinese outlet Yicai reported cuts of 48% for two high doses in some provinces. Reuters
China has become an important battleground as local drugmakers move into the category and the market braces for more competition when Novo’s semaglutide patent expires in 2026 in China, Reuters said. The agency also cited estimates that more than 65% of China’s population could be overweight or obese by 2030, underlining the scale of the opportunity. Reuters
The price pressure in China is colliding with another shift: drugmakers are trying to sell weight-loss therapy more like a consumer product, with more direct access through telehealth and cash-paying channels. Reuters reported that Novo’s once-daily Wegovy pill is expected to launch in early January 2026 and Lilly’s oral drug orforglipron is under regulatory review, with both companies aiming to start low-dose pills at $149 a month for U.S. cash-paying customers; Lilly has said repeat cash buyers would pay no more than $399 a month. Lilly CEO Dave Ricks said, “I can charge less and get it to more people at scale.” Reuters
Cash-pay — customers paying out of pocket rather than through insurance — has become a larger slice of the market than many investors expected. Reuters cited IQVIA data shared with the news agency by an analyst showing cash-pay customers account for about 10% of Wegovy weekly U.S. prescriptions and roughly 30% for Lilly’s Zepbound. Reuters
For Lilly shareholders, the near-term question is how much volume growth lower prices can unlock in new markets without sparking a broader reset in expected margins. Investors also watch whether the coming wave of daily pills changes consumer behavior enough to widen the market rather than cannibalize injections.
In separate disclosures, a Form 4 filing with the U.S. Securities and Exchange Commission showed Lilly Endowment Inc — listed as a director and 10% owner — reported selling 2,629 shares on Dec. 24 at a weighted average price of $1,085.173. A Form 4 is the SEC’s required report for insider transactions. SEC
Novo Nordisk remains Lilly’s closest global rival in obesity treatment, and the latest China discounting points to a more price-competitive phase as both companies push to expand access. Reuters also noted Chinese rivals, including Innovent Biologics, are among the competitors pressing incumbents in the market. Reuters
Traders are watching for any response from Lilly on the scale of China price cuts, how quickly pharmacies and delivery platforms adjust prices, and whether lower pricing feeds through into demand. In the U.S., the next signpost is how aggressively the companies pursue cash-pay channels as pill launches begin and regulators weigh additional access and coverage pathways. Reuters
